

- I. Claims 1-4, 29 and 32, drawn to polypeptides and compositions or kits comprising same, classified in class 530, subclass 350.
- II. Claims 5-14, drawn to nucleic acids, and vectors or host cells comprising same, classified in class 536, subclass 23.1.
- III. Claims 15-18, 31 and 34, drawn to antibodies and compositions comprising the same, classified in class 530, subclass 387.1.
- IV. Claim 19, drawn to method of detecting nucleic acid, classified in class 435, subclass 6.
- V. Claim 20, drawn to method of identifying a polypeptide binding agent.
- VI. Claim 21, drawn to method of identifying a potential therapeutic agent.
- VII. Claim 22, drawn to method for modulating activity of a polypeptide comprising exposing to an agent.
- VIII. Claims 23, 24 and 39, drawn to method of therapeutically administering polypeptide, classified in class 514, subclass 2.
- IX. Claims 25, 26, 30, and 33, drawn to gene therapy compositions and methods, classified in class 514, subclass 44.
- X. Claims 27, 28, and 40, drawn to methods of therapeutically administering antibody, classified in class 424, subclass 130.1.
- XI. Claims 35 and 36, drawn to methods of screening for a modulator of activity or latency or predisposition to a pathology comprising exposing a polypeptide to an agent.